P-GP in English translation

• p-gp

Examples of using P-gp in Croatian and their translations into English

Očekuje se da će istodobna primjena kolhicina i sakvinavira/ritonavira povećati koncentracije kolhicina u plazmi zbog inhibicije P-gp i/ili CYP3A4 inhibitorom proteaze.
Concomitant use of colchicine and saquinavir/ritonavir is expected to increase plasma levels of colchicine due to P-gp and/or CYP3A4 inhibition by the protease inhibitor.

Dabigatran: Učinak konkomitantne primjene kanagliflozina(slabi P-gp inhibitor) na dabigatran eteksilat(P-gp supstrat) nije ispitan.
Dabigatran: The effect of concomitant administration of canagliflozin(a weak P-gp inhibitor) on dabigatran etexilate(a P-gp substrate) has not been studied.

In vitro podaci pokazuju da ulipristalacetat u klinički značajnim koncentracijama može biti inhibitor P-gp.
In vitro data indicate that ulipristal acetate may be an inhibitor of P-gp at clinically relevant concentrations.

efluks transporteri su P-gp i BCRP.
efflux transported by P-gp and BCRP.

AUC za 29% odnosno 27%, za P-gp supstrat digoksina u zdravih dobrovoljaca.
AUC by 29% and 27%, respectively, of the P-gp substrate digoxin in healthy volunteers.

U ispitivanju interakcija među lijekovima u zdravih dobrovoljaca ispitivan je utjecaj P-gp inhibitora verapamila na farmakokinetiku supkutano primijenjenog pasireotida.
The influence of the P-gp inhibitor verapamil on the pharmacokinetics of subcutaneous pasireotide was tested in a drug-drug interaction study in healthy volunteers.

Nije poznato postoji li mogućnost da avanafil interferira s transportom drugih lijekova posredovanih P-gp.
The potential of avanafil to interfere with the transport of other medicinal products mediated by P-gp is not known.

Lijekove s uskim terapijskim rasponom koji su supstrati P-gp(npr. kolhicin,
Medicinal products with a narrow therapeutic range that are substrates for P-gp(e.g. colchicine,

Sonidegib nije inhibirao apikalne efluksne prijenosnike, P-gp ili MRP2, prijenosnike unosa u jetru OATP1B1
Sonidegib did not inhibit apical efflux transporters, P-gp or MRP2, hepatic uptake transporters OATP1B1

Stoga se preporučuje primjena snažnih P-gp inhibitora(uključujući, ali ne ograničeno na ritonavir,
Therefore, it is recommended to administer strong P-gp inhibitors(including but not limited to ritonavir,

Kliničko ispitivanje interakcija lijekova pokazalo je da istovremena primjena jedne doze od 400 mg idelalisiba s 400 mg ketokonazola jednom dnevno(jakim CYP3A, P-gp i BCRP inhibitorom) izaziva porast Cmax idelalisiba za 26%
A clinical drug interaction study found that co-administration of a single dose of 400 mg idelalisib with 400 mg once daily ketoconazole(a strong CYP3A, P-gp and BCRP inhibitor) resulted in a 26% increase in Cmax

CYP2C9 i P-gp za više informacija vidjeti dio 5.2.
CYP2C9 and P-gp for more information see section 5.2.

Istodobna primjena Sovaldija s lijekovima koji inhibiraju P-gp i/ili BCRP može povećati koncentraciju sofosbuvira u plazmi bez povećavanja koncentracije GS-331007 u plazmi pa se stoga Sovaldi može istodobno primjenjivati s inhibitorima P-gp i/ili BCRP.
Co-administration of Sovaldi with medicinal products that inhibit P-gp and/or BCRP may increase sofosbuvir plasma concentration without increasing GS-331007 plasma concentration, thus Sovaldi may be co-administered with P-gp and/or BCRP inhibitors.

u bolesnika koji istovremeno uzimaju određene lijekove(poznatiji kao P-gp inhibitori) koji mogu utjecati na uklanjanje.
in those who are also taking certain medicines(known as P-gp inhibitors) that can interfere with the removal of.

istodobno liječenih antitrombocitnim lijekovima ili P-gp inhibitorima.
concomitant medication use such as anti-platelets or P-gp inhibitors.

na CYP2C9 i P-gp nakon nekoliko dana liječenja.
on CYP2C9 and P-gp after several days of treatment.

Istovremena primjena lurasidona s digoksinom(P-gp supstratom) nije povećavala izloženost digoksinu
Coadministration of lurasidone with digoxin(a P-gp substrate) did not increase the exposure to digoxin

Edoksaban je supstrat efluksnog prijenosnika P-glikoproteina(P-gp), ali nije supstrat prijenosnika za unos,
Edoxaban is a substrate for the efflux transporter P-glycoprotein(P- gp), but not a substrate

Stoga ponatinib može smanjiti plazmatske koncentracije istovremeno primijenjenih supstrata P-gp(poput digoksina, dabigatrana,
Therefore, ponatinib may have the potential to increase plasma concentrations of co-administered substrates of P-gp(e.g., digoxin,

tj. doza P-gp inhibitora se mora uzeti sa što je moguće duljim vremenskim razmakom od uzimanja doze GIOTRIFA.
i.e. the P-gp inhibitor dose should be taken as far apart in time as possible from the GIOTRIF dose.